Focal therapy for prostate cancer: patient selection and evaluation
Date
2012Keyword
Abstract
Recent stage migration toward low-risk prostate cancer, overtreament of biologically insignificant tumors with radical prostatectomy at the additional expense of a non-negligible morbidity and undertreatment of patients improperly selected for active surveillance are the main reasons that have fuelled the concept of focal therapy. Optimal selection of patients is the key for the successful implementation of focal therapy. Selection criteria for focal therapy vary widely and depend on clinical, histological and imaging characteristics of the patients that are highlighted in this article. In addition, the rationales, merits and limitations of the available methods for the assessment of potential candidates, the evaluation of treatment efficacy and follow-up of these patients are discussed.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Effects of varenicline therapy in combination with advanced behavioral support on smoking cessation and quality of life in inpatients with acute exacerbation of COPD, bronchial asthma, or community-acquired pneumonia: A prospective, open-label, preference-based, 52-week, follow-up trial
Politis A., Ioannidis V., Gourgoulianis K.I., Daniil Z., Hatzoglou C. (2018)Quitting smoking is the most important element in the therapeutic management of chronic respiratory diseases. Combining pharmacotherapy with behavioral support increases smoking cessation success rates. In addition, ... -
Is locally advanced head-neck cancer one more candidate for accelerated hypofractionation?
KOUKOURAKIS I.M., ZYGOGIANNI A., KOULOULIAS V., KYRGIAS G., PANTELIADOU M., NANOS C., ABATZOGLOU I., KOUKOURAKIS M.I. (2021)Background/Aim: Hypofractionated accelerated radiotherapy (HypoAR) is widely applied for the treatment of early laryngeal cancer. Its role in locally advanced head-neck cancer (LA-HNC) is unexplored. Patients and Methods: ... -
Local intracerebral inhibition of IRE1 by MKC8866 sensitizes glioblastoma to irradiation/chemotherapy in vivo
Le Reste P.J., Pineau R., Voutetakis K., Samal J., Jégou G., Lhomond S., Gorman A.M., Samali A., Patterson J.B., Zeng Q., Pandit A., Aubry M., Soriano N., Etcheverry A., Chatziioannou A., Mosser J., Avril T., Chevet E. (2020)Glioblastoma multiforme (GBM) is the most severe primary brain cancer. Despite an aggressive treatment comprising surgical resection and radio/chemotherapy, patient's survival post diagnosis remains short. A limitation for ...